Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced the launch of a new sub-brand, RenBiologics?, to represent the company?s antibody discovery business division. RenBiologics business will cover out-licensing/co-development of the company?s extensive library of fully human antibodies, as well as licensing of RenMice®, the company?s fully human antibody/TCR discovery platforms. The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company?s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.